4//SEC Filing
Horga Maria Arantxa 4
Accession 0000950170-24-010970
CIK 0001593899other
Filed
Feb 1, 7:00 PM ET
Accepted
Feb 2, 9:29 PM ET
Size
10.7 KB
Accession
0000950170-24-010970
Insider Transaction Report
Form 4
Horga Maria Arantxa
Chief Medical Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2024-01-31−41,534→ 83,066 total→ Common Stock (41,534 underlying) - Award
Stock Option (Right to Buy)
2024-01-31+192,800→ 192,800 totalExercise: $4.16Exp: 2034-01-30→ Common Stock (192,800 underlying) - Sale
Common Stock
2024-02-01$3.84/sh−15,870$60,963→ 25,664 total - Exercise/Conversion
Common Stock
2024-01-31+41,534→ 41,534 total
Footnotes (4)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 14, 2022.
- [F3]The original grant of 124,600 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.
- [F4]The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028.
Documents
Issuer
Atea Pharmaceuticals, Inc.
CIK 0001593899
Entity typeother
Related Parties
1- filerCIK 0001829614
Filing Metadata
- Form type
- 4
- Filed
- Feb 1, 7:00 PM ET
- Accepted
- Feb 2, 9:29 PM ET
- Size
- 10.7 KB